Reuters logo
BRIEF-Aptevo Therapeutics amends collaboration agreement with Morphosys AG for Novel Immunotherapeutic
December 15, 2016 / 7:10 PM / 9 months ago

BRIEF-Aptevo Therapeutics amends collaboration agreement with Morphosys AG for Novel Immunotherapeutic

Dec 15 (Reuters) - Aptevo Therapeutics Inc :

* Under terms of third amendment, Aptevo Research and Development will bear 75 pct of all development costs with respect to MOR209/es414

* Beyond January 1, 2019, Aptevo will bear 36 pct and Morphosys will bear 64 pct of such development costs

* Under revised termination rights, Morphosys can terminate agreement within one week following receipt, discussion of test results

* On December 12, 2016, Aptevo Research and Development entered into a third amendment to license and co-development agreement- sec filing

* Also, under terms of third amendment Morphosys will bear 25 pct of costs, during period from January 1, 2017 through June 30, 2017

* During period from july 1, 2017 through december 31, 2018, Aptevo Research and Development will bear 49 pct of development costs, Morphosys will bear 51 pct

* Under revised termination rights Morphosys can terminate collaboration agreement at any time during last two weeks of June 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below